Spago Nanomedical AB

ST:SPAGO Sweden Biotechnology
Market Cap
$6.49 Million
Skr72.77 Million SEK
Market Cap Rank
#31936 Global
#482 in Sweden
Share Price
Skr0.11
Change (1 day)
-9.09%
52-Week Range
Skr0.09 - Skr0.40
All Time High
Skr19.04
Categories
Companies in Sweden Biotechnology
About

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well… Read more

Spago Nanomedical AB (SPAGO) - Net Assets

Latest net assets as of December 2025: Skr30.75 Million SEK

Based on the latest financial reports, Spago Nanomedical AB (SPAGO) has net assets worth Skr30.75 Million SEK as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr36.68 Million) and total liabilities (Skr5.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr30.75 Million
% of Total Assets 83.82%
Annual Growth Rate 6.43%
5-Year Change -83.36%
10-Year Change -57.21%
Growth Volatility 64.74

Spago Nanomedical AB - Net Assets Trend (2011–2025)

This chart illustrates how Spago Nanomedical AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Spago Nanomedical AB (2011–2025)

The table below shows the annual net assets of Spago Nanomedical AB from 2011 to 2025.

Year Net Assets Change
2025-12-31 Skr30.75 Million -7.49%
2024-12-31 Skr33.23 Million -19.56%
2023-12-31 Skr41.32 Million -79.04%
2022-12-31 Skr197.16 Million +6.68%
2021-12-31 Skr184.81 Million +15.74%
2020-12-31 Skr159.67 Million +16.02%
2019-12-31 Skr137.63 Million +12.61%
2018-12-31 Skr122.22 Million +13.40%
2017-12-31 Skr107.78 Million +50.02%
2016-12-31 Skr71.84 Million +9.84%
2015-12-31 Skr65.41 Million +16.69%
2014-12-31 Skr56.05 Million +46.82%
2013-12-31 Skr38.18 Million -9.64%
2012-12-31 Skr42.25 Million +228.96%
2011-12-31 Skr12.84 Million --

Equity Component Analysis

This analysis shows how different components contribute to Spago Nanomedical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 71500000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock Skr6.62 Million 21.52%
Other Comprehensive Income Skr-384.00K -1.25%
Other Components Skr24.51 Million 79.73%
Total Equity Skr30.75 Million 100.00%

Spago Nanomedical AB Competitors by Market Cap

The table below lists competitors of Spago Nanomedical AB ranked by their market capitalization.

Company Market Cap
Southern ITS International Inc
PINK:SITS
 		$4.16 Million
Spectrumone publ AB
ST:SPEONE
 		$4.16 Million
Kumwell Corporation Public Company Limited
BK:KUMWEL
 		$4.16 Million
AUTO NEJIMA
BC:AUTO-NEJIMA
 		$4.16 Million
Comelf SA
RO:CMF
 		$4.16 Million
Streamplay Studio Ltd
AU:SP8
 		$4.16 Million
Shiva Texyarn Limited
NSE:SHIVATEX
 		$4.16 Million
Sung Gang Asset Management Ltd
TWO:6240
 		$4.16 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Spago Nanomedical AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 33,235,000 to 30,746,000, a change of -2,489,000 (-7.5%).
  • Net loss of 26,554,000 reduced equity.
  • Other comprehensive income increased equity by 251,966,000.
  • Other factors decreased equity by 227,901,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr-26.55 Million -86.37%
Other Comprehensive Income Skr251.97 Million +819.51%
Other Changes Skr-227.90 Million -741.24%
Total Change Skr- -7.49%

Book Value vs Market Value Analysis

This analysis compares Spago Nanomedical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.34x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 0.00x to 1.34x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2011-12-31 Skr27.37 Skr0.11 x
2012-12-31 Skr5.02 Skr0.11 x
2013-12-31 Skr4.53 Skr0.11 x
2014-12-31 Skr5.13 Skr0.11 x
2015-12-31 Skr4.88 Skr0.11 x
2016-12-31 Skr3.93 Skr0.11 x
2017-12-31 Skr4.74 Skr0.11 x
2018-12-31 Skr2.77 Skr0.11 x
2019-12-31 Skr3.06 Skr0.11 x
2020-12-31 Skr2.75 Skr0.11 x
2021-12-31 Skr2.21 Skr0.11 x
2022-12-31 Skr1.04 Skr0.11 x
2023-12-31 Skr0.21 Skr0.11 x
2024-12-31 Skr0.11 Skr0.11 x
2025-12-31 Skr0.08 Skr0.11 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Spago Nanomedical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -86.37%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -6076.43%
  • • Asset Turnover: 0.01x
  • • Equity Multiplier: 1.19x
  • Recent ROE (-86.37%) is below the historical average (-29.00%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2011 -5.57% -72.88% 0.04x 1.97x Skr-2.00 Million
2012 -10.92% -2078.83% 0.00x 1.27x Skr-8.84 Million
2013 -14.08% -2286.84% 0.00x 1.56x Skr-8.92 Million
2014 -11.65% -11353.70% 0.00x 1.44x Skr-11.39 Million
2015 -10.39% -90.37% 0.10x 1.14x Skr-13.33 Million
2016 -10.49% -13000.00% 0.00x 1.11x Skr-14.72 Million
2017 -8.77% -20121.28% 0.00x 1.04x Skr-20.23 Million
2018 -9.08% -37.42% 0.23x 1.03x Skr-23.31 Million
2019 -14.74% -67600.00% 0.00x 1.02x Skr-34.04 Million
2020 -11.84% -5527.19% 0.00x 1.02x Skr-34.87 Million
2021 -21.14% -5920.45% 0.00x 1.04x Skr-57.56 Million
2022 -19.94% -3729.51% 0.01x 1.04x Skr-59.02 Million
2023 -102.19% -3509.81% 0.02x 1.28x Skr-46.35 Million
2024 -97.82% -1701.15% 0.05x 1.19x Skr-35.83 Million
2025 -86.37% -6076.43% 0.01x 1.19x Skr-29.63 Million

Industry Comparison

This section compares Spago Nanomedical AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $60,327,288
  • Average return on equity (ROE) among peers: -132.31%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Spago Nanomedical AB (SPAGO) Skr30.75 Million -5.57% 0.19x $4.16 Million
2cureX AB (2CUREX) $20.24 Million -15.50% 0.13x $1.38 Million
Abliva AB (ABLI) $63.04 Million -23.59% 0.13x $46.60 Million
Ascelia Pharma AB (publ) (ACE) $180.86 Million -72.56% 0.21x $25.35 Million
AcouSort AB (ACOU) $20.11 Million -65.68% 1.12x $4.82 Million
Active Biotech AB (ACTI) $162.30 Million -107.35% 0.93x $3.55 Million
Alzinova AB (ALZ) $29.39 Million -8.53% 0.08x $4.19 Million
AlzeCure Pharma (ALZCUR) $110.75 Million -64.44% 0.06x $12.56 Million
Annexin Pharmaceuticals AB (ANNX) $20.64 Million -216.80% 0.22x $4.92 Million
Alligator Bioscience AB (ATORX) $6.86 Million -748.65% 15.13x $723.60K
Biosergen AS (BIOSGN) $-10.92 Million 0.00% 0.00x $2.76 Million